Cascadian Therapeutics

The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Type
Public
HQ
Seattle, US
Size (employees)
57 (est)+8%
Cascadian Therapeutics is headquartered in Seattle, US

Cascadian Therapeutics Office Locations

Cascadian Therapeutics has an office in Seattle
Seattle, US (HQ)
500 2601 4th Ave

Cascadian Therapeutics Data and Metrics

Cascadian Therapeutics Financial Metrics

USD

Market capitalization (28-Jun-2017)

209.7 m

Closing share price (28-Jun-2017)

3.6

Cash (31-Dec-2016)

13.7 m
Cascadian Therapeutics's current market capitalization is $209.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.3 m10.5 m27.9 m13.7 m

Current Assets

60.9 m58.9 m58 m64.5 m

PP&E

1.7 m1.6 m1.8 m1.4 m

Goodwill

2.1 m16.7 m16.7 m16.7 m

Total Assets

77.7 m103.4 m96.6 m83.3 m

Accounts Payable

533 k689 k439 k824 k

Current Liabilities

4.7 m4.7 m4.8 m8.8 m

Common Stock

353.8 m

Additional Paid-in Capital

154.8 m224.5 m249.6 m297.9 m

Retained Earnings

(432.1 m)(482 m)(514.6 m)(572.3 m)

Total Equity

83.7 m74.4 m

Financial Leverage

1.2 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(38.8 m)(50 m)(32.6 m)(57.7 m)

Depreciation and Amortization

489 k512 k613 k642 k

Accounts Payable

(600 k)144 k(250 k)385 k

Cash From Operating Activities

(36.3 m)(48.4 m)(28.9 m)(36.8 m)

Purchases of PP&E

(252 k)(380 k)(771 k)(147 k)

Cash From Investing Activities

(2.7 m)9.2 m23.7 m(21 m)

Cash From Financing Activities

26.1 m40.4 m22.6 m43.6 m

Interest Paid

276 k
Y, 2016

Financial Leverage

1.1 x

Cascadian Therapeutics Operating Metrics

FY, 2016

Patents (US)

1

Patents (foreign)

18

Patents Licensed

222

Cascadian Therapeutics Market Value History

Cascadian Therapeutics Company Life and Culture

You may also be interested in